143 related articles for article (PubMed ID: 32208118)
1. Novel and Predictive QSAR Model for Steroidal and Nonsteroidal 5α- Reductase Type II Inhibitors.
Mando H; Hassan A; Gharaghani S
Curr Drug Discov Technol; 2021; 18(2):317-332. PubMed ID: 32208118
[TBL] [Abstract][Full Text] [Related]
2. Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids.
Thareja S; Rajpoot T; Verma SK
Steroids; 2015 Mar; 95():96-103. PubMed ID: 25582615
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
5. Exploration of Novel 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia by 2D/3D QSAR, Cytotoxicity Pre-ADME and Docking Studies.
Dhingra R; Malhotra M; Sharma V; Bhardwaj TR; Dhingra N
Curr Top Med Chem; 2018; 18(32):2816-2834. PubMed ID: 30659542
[TBL] [Abstract][Full Text] [Related]
6. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.
Cabeza M; Sánchez-Márquez A; Garrido M; Silva A; Bratoeff E
Curr Med Chem; 2016; 23(8):792-815. PubMed ID: 26861003
[TBL] [Abstract][Full Text] [Related]
8. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
Pais P
Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
[TBL] [Abstract][Full Text] [Related]
9. Steroidal 5α-Reductase Inhibitors: A Comparative 3D-QSAR Study Review.
Thareja S
Chem Rev; 2015 Apr; 115(8):2883-94. PubMed ID: 25785489
[No Abstract] [Full Text] [Related]
10. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
12. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
13. Bisphenol A exposure during adulthood alters expression of aromatase and 5α-reductase isozymes in rat prostate.
Castro B; Sánchez P; Torres JM; Preda O; del Moral RG; Ortega E
PLoS One; 2013; 8(2):e55905. PubMed ID: 23405234
[TBL] [Abstract][Full Text] [Related]
14. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia.
Buonocore D; Verri M; Cattaneo L; Arnica S; Ghitti M; Dossena M
Arch Ital Urol Androl; 2018 Sep; 90(3):199-202. PubMed ID: 30362688
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening approach for the discovery of selective 5α-reductase type II inhibitors for benign prostatic hyperplasia treatment.
Mandour AA; Elkaeed EB; Hagras M; Refaat HM; Ismail NS
Future Med Chem; 2023 Dec; 15(23):2149-2163. PubMed ID: 37955117
[No Abstract] [Full Text] [Related]
16. Self organizing molecular field analysis on a series of human 5alpha-reductase inhibitors: unsaturated 3-carboxysteroid.
Thareja S; Aggarwal S; Bhardwaj TR; Kumar M
Eur J Med Chem; 2009 Dec; 44(12):4920-5. PubMed ID: 19716209
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors.
Srivilai J; Minale G; Scholfield CN; Ingkaninan K
Assay Drug Dev Technol; 2019; 17(2):44-57. PubMed ID: 30575417
[TBL] [Abstract][Full Text] [Related]
18. A new label-free screen for steroid 5α-reductase inhibitors using LC-MS.
Srivilai J; Rabgay K; Khorana N; Waranuch N; Nuengchamnong N; Ingkaninan K
Steroids; 2016 Dec; 116():67-75. PubMed ID: 27789379
[TBL] [Abstract][Full Text] [Related]
19. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
20. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
